Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of VX-659 Combination Therapy in Cystic Fibrosis
NCT03447262Phase 3Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of bamocaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jul 2018; status: terminated.
02
Drugs
bamocaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03447262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03447262.